Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

Myrna Candelaria,D. González,Marcia Torresan Delamain,Daniel Oscar Bar,Surender Kumar Beniwal,Lokanatha Dasappa,David Hugo Flores,John Querol,Toh See Guan,Oleg Nikolaevich Lipatov,Elena Volodicheva,Moosa Patel,Sayyed Reza Safaee Nodehi,Laura Fogliatto,Alexandra Paravisini,Luis Pérez Díaz

Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

2019

Myrna Candelaria
D. González
Marcia Torresan Delamain
Daniel Oscar Bar
Surender Kumar Beniwal
Lokanatha Dasappa
David Hugo Flores
John Querol
Toh See Guan
Oleg Nikolaevich Lipatov
Elena Volodicheva
Moosa Patel
Sayyed Reza Safaee Nodehi
Laura Fogliatto
Alexandra Paravisini
Luis Pérez Díaz

AbstractThis multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R...

Keywords:

Immunology
Diffuse large B-cell lymphoma
Biosimilar
Rituximab
CHOP
Oncology
Internal medicine
Medicine
Immunogenicity
Pharmacodynamics
Randomized controlled trial
Clinical trial
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations